Skip to main content

Table 5 The predictive value of PCDH8 methylation for the five-year overall survival in non muscle invasive bladder cancer (n = 233)

From: Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer

Variable

Univariate analysis

Multivariate analysis

HR

95% CI

P

HR

95% CI

P

PCDH8 methylation (M vs. U)

4.653

1.237-7.314

<0.0001

3.017

1.542-8.251

0.0015

Age (>65 vs. ≦65)

1.135

0.779-6.273

0.3471

   

Sex (Male vs. Female)

0.874

0.645-3.228

0.7361

   

Number (Multiple vs. Single)

1.054

0.798-6.417

0.3784

   

Size (>3 cm vs. ≤3 cm)

1.253

0.913-10.257

0.3095

   

Grade (G3 vs. G1 / G2)

3.876

1.643-6.024

0.0021

1.852

1.144-5.964

0.0324

Stage (T1 vs. Ta)

1.015

0.792-7.572

0.4338

   
  1. HR: Hazard Ratio; M: Methylated; U: Unmethylated.